Research progress on pancreatic injury induced by glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus
10.3760/cma.j.cn114015-20240617-00452
- VernacularTitle:胰高血糖素样肽1受体激动剂致2型糖尿病患者胰腺损伤的研究进展
- Author:
Weihao JIANG
1
;
Yuan BIAN
;
Enwu LONG
Author Information
1. 西南医科大学药学院，泸州 646000
- Publication Type:Journal Article
- Keywords:
Glucagon-like peptide-1 receptor agonists;
Diabetes mellitus, type 2;
Drug-related side effects and adverse reactions;
Pancreatic injury
- From:
Adverse Drug Reactions Journal
2024;26(12):749-755
- CountryChina
- Language:Chinese
-
Abstract:
Glucagon-like peptide-1 receptor agonists (GLP-1RA) are used to treat type 2 diabetes mellitus (T2DM) by enhancing insulin secretion and inhibiting glucagon secretion. GLP-1RA has good efficacy and safety, but it may have the risk of pancreatic injury. Its incidence is low, but it is more harmful. At present, the research conclusions of GLP-1RA-related pancreatic injury are not consistent. This article reviews the research progress of GLP-1RA-related pancreatic injury from the aspects of occurrence, possible mechanism, related clinical research, clinical manifestations, and management measures. The possible mechanisms include activation of stellate cells, induction of proliferation and metaplasia of pancreatic ductal epithelial cells, presence of immune rejection, and influence on the expression of pancreatic injury related genes. Pancreatitis is more common in GLP-1RA-related pancreatic injury, and its clinical manifestations are abdominal pain, nausea, vomiting, and the elevation of lipase and amylase. It is suggested that patients should be given necessary medication education before medication. Once relevant symptoms occur, acute pancreatitis should be considered and the medication should be stopped immediately. If pancreatitis is confirmed, GLP‐1RA treatment is not recommended.
